title: Survival, prognostic factors, and therapeutic efficacy in low-grade glioma: a retrospective study in 379 patients.
abstract: OBJECTIVE
  We report survival, prognostic factors, and treatment efficacy in low-grade glioma.
  
  
  METHODS
  A total of 379 patients with histologic intracranial low-grade glioma received post-operative radiotherapy (n = 361) and intraarterial carmustine (BCNU) chemotherapy (n = 153). Overall survival and prognostic factors were evaluated with the SPSS statistical program (SPSS Inc, Chicago, IL).
  
  
  RESULTS
  Median survival (all patients) was 100 months (95% confidence interval [CI], B7 to 113); in age group 0 to 19 years (n = 41), 226 months; in age group 20 to 49 years (n = 263), 106 months; in age group 50 to 59 years (n = 49), 76 months; and for older patients (n = 26), 39 months. Projected survival at 10 and 15 years was 42% and 29%, respectively. Patient age, World Health Organization (WHO) performance status, tumor computed tomography (CT) contrast enhancement, mental changes, or initial corticosteroid dependency were significant independent prognostic factors (p < .05), while histologic subgroup, focal deficits, presence of seizures, prediagnostic symptom duration, tumor category, and tumor stage were not. Patients aged 20 to 49 years with no independent negative prognostic factors (n = 132) had a median survival time of 139 months versus 41 months in patients with two or more factors (n = 33). Patients who presented with symptoms of expansion (n = 97) survived longer when resected (P < .03); otherwise no survival benefit was associated with initial tumor resection compared with biopsy. Intraarterial chemotherapy and radiation doses more than 55 Gy were not associated with prolonged survival. Among 66 reoperated patients, 45% progressed to high-grade histology within 25 months.
  
  
  CONCLUSIONS
  Prognosis in low-grade glioma following postoperative radiotherapy seems largely determined by the inherent biology of the glioma and patient age at diagnosis.
authors.affiliation: Department of Oncology, Norwegian Radium Hospital, Oslo, Norway.
authors.forename: K
authors.initials: K
authors.lastname: Lote
authors.forename: T
authors.initials: T
authors.lastname: Egeland
authors.forename: B
authors.initials: B
authors.lastname: Hager
authors.forename: B
authors.initials: B
authors.lastname: Stenwig
authors.forename: K
authors.initials: K
authors.lastname: Skullerud
authors.forename: J
authors.initials: J
authors.lastname: Berg-Johnsen
authors.forename: I
authors.initials: I
authors.lastname: Storm-Mathisen
authors.forename: H
authors.initials: H
authors.lastname: Hirschberg
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D018906:Antineoplastic Agents, Alkylating / Q000627:therapeutic use; D001932:Brain Neoplasms / Q000401:mortality / Q000473:pathology / Q000628:therapy; D002330:Carmustine / Q000627:therapeutic use; D002648:Child; D002675:Child, Preschool; D003131:Combined Modality Therapy; D005260:Female; D005910:Glioma / Q000401:mortality / Q000473:pathology / Q000628:therapy; D006801:Humans; D007223:Infant; D007261:Infusions, Intra-Arterial; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D016016:Proportional Hazards Models; D011879:Radiotherapy Dosage; D012189:Retrospective Studies; D012307:Risk Factors; D016019:Survival Analysis; D016896:Treatment Outcome
chemical_list: D018906:Antineoplastic Agents, Alkylating; D002330:Carmustine